Atezolizumab as first-line monotherapy for mNSCLC

June 10, 2020 0 By FM

Atezolizumab (Tecentriq) has been granted approval by the US FDA as a first-line treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression (PD-L1 stained = 50% of tumour cells [TC = 50%] or PD-L1 stained tumour-infiltrating [IC] covering = 10% of the tumour area [IC = 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumour aberrations.

This approval is based on an interim analysis from the phase III IMpower110 study, which showed that atezolizumab monotherapy improved overall survival (OS) by 7.1 months compared with chemotherapy (median OS=20.2 versus 13.1 months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89; p=0.0106) in people with high PD-L1 expression (TC3/IC3-wild-type [WT]).